Novartis: gene therapy prolongs survival in SMA trial
(CercleFinance.com) - Interim data from a Phase 3 trial on AveXis's Zolgensma in type 1 spinal muscular atrophy has showed prolonged event-free survival, the Novartis gene therapy unit said on Wednesday.
The treatment also reached significant milestones, compared to untreated natural history, consistent with data from a pivotal Phase 1 trial, AveXis said.
This data builds upon the body of evidence supporting the use of Zolgensma for type 1 SMA, AveXis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The treatment also reached significant milestones, compared to untreated natural history, consistent with data from a pivotal Phase 1 trial, AveXis said.
This data builds upon the body of evidence supporting the use of Zolgensma for type 1 SMA, AveXis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.